AdAlta (ASX:1AD) has moved to strengthen its strategic and market-facing capabilities with the appointment of experienced corporate executive Fadi Diab to its Board as a non-executive director.
The clinical-stage company, focused on advancing cellular immunotherapies and protein-based treatments, announced the appointment as part of its broader effort to accelerate value creation across its pipeline and partnerships. The move comes at a time when AdAlta is actively pursuing multiple avenues for expansion through its East to West strategy and its proprietary i-body enabled assets.
Chair Dr Paul MacLeman welcomed the addition, emphasising both timing and fit. “We are pleased to welcome Fadi Diab to our Board. AdAlta is advancing multiple growth and value realisation opportunities across its East to West cellular immunotherapy strategy and existing i body enabled assets as well as new opportunities being presented to it. Fadi’s investor relations, communications and market analytics capabilities and connections will be invaluable as we navigate these opportunities.”
Diab brings more than a decade of experience spanning financial institutions, operational leadership, and large-scale transformation programs. His background includes overseeing teams that process billions of dollars in payments and delivering initiatives that have received national industry recognition. He currently serves as Managing Director of Phoenix Global Investments, where he advises companies on investor relations strategy and market engagement, and holds non-executive roles across several ASX-listed entities.
The appointment reflects a deliberate effort by AdAlta to deepen its expertise in capital markets communication and strategic positioning, particularly as it seeks to bridge innovation between Asian cellular therapy development and Western regulatory pathways. Through its subsidiary AdCella, the company is pursuing a model that combines licensed assets from Asia with Australian clinical and manufacturing capabilities, aiming to position therapies for global commercialisation.
This approach is underpinned by a focus on solid tumours, which account for the vast majority of cancer cases yet remain underserved by current immunotherapies. AdAlta is targeting this gap with a portfolio that includes BZDS1901, a next-generation CAR T therapy designed for mesothelioma and other difficult-to-treat cancers, alongside AD 214, a fusion protein candidate for fibrotic diseases, and WD 34, an early-stage program targeting malaria.